A CRISPR mediated point-of-care assay for the detection of mucosal calprotectin in an animal model of ulcerative colitis.

ABSTRACT: Inflammatory bowel disease (IBD) is a chronic disorder associated with inflammation in the gastrointestinal tract, leading to a range of debilitating symptoms. Fecal calprotectin is an established biomarker for ulcerative colitis (UC), one of the main IBD diseases, which provides indications of the presence and severity of inflammation in the digestive tract. Enzyme-Linked Immunosorbent Assay (ELISA) as a gold standard approach for fecal calprotectin detection is time-consuming and impractical in point-of-care settings. Moreover, obtaining fecal samples from patients is challenging and inhibits longitudinal monitoring. To address these specific problems, we have developed a novel approach for detecting calprotectin which leverages clustered regularly interspaced short palindromic repeats (

SUBMITTER: Chia S 

PROVIDER: S-EPMC11883116 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature